Business Context and Reporting Period
Company: Regentis Biomaterials Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: June 2026 (Event date: June 17, 2026; Filing date: June 18, 2026)
Context: The Company announced a private placement offering to raise capital for clinical trials, regulatory submissions, and operational scale-up.
Key Financial Metrics
Offering Details:
- Gross Proceeds: Approximately $6.5 million (expected).
- Securities Issued: 1,844,543 Ordinary Shares, 12,600 Pre-Funded Warrants, and 1,857,143 Ordinary Warrants.
- Purchase Price: $3.50 per Ordinary Share and accompanying Ordinary Warrant; $3.4999 per Pre-Funded Warrant and accompanying Ordinary Warrant.
- Placement Agent Fees: 7.0% cash fee, 1.0% expense allowance, plus reimbursement up to $180,000.
- Placement Agent Warrants: 92,857 warrants (5.0% of aggregate shares/warrants sold) at an exercise price of $4.375.
Financial Position: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics. This filing focuses solely on the terms of the capital raise.
Material Changes
Capital Structure: The Company will issue new equity and warrants, resulting in dilution to existing shareholders. The offering includes a 4.99% beneficial ownership limitation (increasable to 9.99%) for purchasers.
Restrictions:
- Market Standstill: The Company is restricted from issuing new shares or filing registration statements (except for employee plans) for 90 days following the effective date of the resale registration.
- Lock-up: Officers and directors are locked up for 90 days following the effective date.
- Variable Rate Transactions: Prohibited for 180 days following the effective date.
Guidance, Outlook, and Risks
Use of Proceeds:
- Support pivotal clinical trial for GelrinC.
- Advance pre-market approval (PMA) submission to the FDA.
- Advance Gelrin technology platform and product optimization.
- Support operational readiness, manufacturing scale-up, and regulatory affairs.
- Facilitate European market entry (MDR compliance, marketing).
- Working capital and general corporate purposes.
Warrant Terms:
- Pre-Funded Warrants: Exercise price $0.0001; immediately exercisable; no expiration.
- Ordinary Warrants: Exercise price $4.20; immediately exercisable; expire 5 years from issuance.
Risks and Contingencies:
- Registration Rights: The Company must file a registration statement within 15 trading days of closing and use commercially reasonable efforts to make it effective within 30 days (or 60 days if a full review is required). Failure to meet these deadlines may trigger liquidated damages.
- Liquidity: Securities are sold under Section 4(a)(2) and Rule 506(c) exemptions; they cannot be resold in the U.S. without registration or an applicable exemption.
Investor Verification Checklist
- Verify the closing date of the Offering (expected on or about June 23, 2026).
- Confirm the final net proceeds after deducting placement agent fees and offering expenses.
- Monitor the filing of the Registration Statement (due 15 trading days post-closing) to ensure compliance with resale registration timelines.
- Review the impact of the new share issuance on fully diluted share count and per-share ownership.
- Track progress on the GelrinC pivotal clinical trial and FDA PMA submission as primary use-of-proceeds milestones.